Oral lactoferrin for the treatment of sepsis and necrotizing enterocolitis in neonates

Cochrane Database of Systematic Reviews

Volumn , Issue 1, 2009, Pages

  Mohan, Pammi ^a   Abrams, Steven A ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b CHILDREN S NUTRITION RESEARCH CENTER   (United States)

Author keywords

Administration, oral; Enterocolitis, necrotizing *drug therapy ; Humans; Infant, newborn; Infant, premature; Lactoferrin *administration dosage; adverse effects ; Sepsis *drug therapy

Indexed keywords

ANTIBIOTIC AGENT; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN; LACTOFERRIN; PENTOXIFYLLINE;

ADD ON THERAPY; ADULT; ANTIBIOTIC THERAPY; CINAHL; CLINICAL TRIAL; COCHRANE LIBRARY; DATA BASE; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; EMBASE; GASTROINTESTINAL SYMPTOM; GESTATIONAL AGE; HUMAN; INFORMATION PROCESSING; LENGTH OF STAY; MEDLINE; META ANALYSIS; NECROTIZING COLITIS; NECROTIZING ENTEROCOLITIS; NERVE CELL DIFFERENTIATION; NEWBORN SEPSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; REVIEW; SIDE EFFECT; STOMACH SECRETION; SURVIVAL RATE; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING;

EID: 70249103790     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD007138.pub2     Document Type: Review

References (32)

1. Zavaleta N, Figueroa D, Rivera J, Sanchez J, Alfaro S, Lonnerdal B. Efficacy of rice-based oral rehydration solution containing recombinant human lactoferrin and lysozyme in peruvian children with acute diarrhea. Journal of Pediatric Gasteroenterology and Nutrition 2007; 44:258-264 (Pubitemid 46188074)
2. Adams-Chapman I, Stoll BJ. Neonatal infection and long-term neurodevelopmental outcome in the preterm infant. Current Opinion in Infectious Diseases 2006;19:290-297 (Pubitemid 43740369)
3. Bell MJ, Ternberg JL, Feigin RD, Keating JP, Marshall R, Barton L, Brotherton T. Neonatal necrotising enterocolitis. Therapeutic decisions based upon clinical staging. Annals of Surgery 1978;187: 1-7.
4. Bellamy W, Takase M, Wakabayashi H, Kawase K, Tomita M. Antibacterial spectrum of lactoferricin B, a potent bactericidal peptide derived from the N-terminal region of bovine lactoferrin. Journal of Applied Bacteriology 1992;73:472-479
5. Blackwell TS, Christman JW. The role of nuclear factor-kappa B in cytokine gene regulation. American Journal of Respiratory Cell and Molecular Biology 1997;17:3-9. (Pubitemid 127500814)
6. Buccigrossi V, deMarco G, Bruzzese E, Ombrato L, Bracale I, Polito G, Guarino A. Lactoferrin induces concentration-dependent functional modulation of intestinal proliferation and differentiation. Pediatric Research 2007;61:410-414
7. Gifford JL, Hunter HN, Vogel HJ. Lactoferricin: a lactoferrin-derived peptide with antimicrobial, antiviral, antitumor and immunological properties. Cellular and Molecular Life Sciences 2005;62: 2588-2598
8. Gomez HF, Ochoa TJ, Herrera-Insua I, Carlin LG, Cleary TG. Lactoferrin protects rabbits from Shigella flexneri-induced inflammatory enteritis. Infection and Immunity 2001;70:7050-7053 (Pubitemid 35387941)
9. Guillen CI,McInnes B, VaughanDM, Kommajosyula S, Van Berkel PH, Leung BP, Aguila A, Brock JH. Enhanced Th1 response to Staphylococcus aureus infection in human lactoferrin-transgenic mice. Journal of Immunology 2002;168:3950-3957 (Pubitemid 34298399)
10. Guntapalli. Safety and efficacy study of recombinant human lactoferrin to treat severe sepsis. ClinicalTrials.gov: NCT00630656.
11. Hayes TG, Falchook GF, Varadhachary GR, Smith DP, Davis LD, Dhingra HM, Hayes BP, Varadhachary A. Phase I trial of oral talactoferrin alfa in refractory solid tumors. Investigational New Drugs 2006;24:233-240 (Pubitemid 43723899)
12. IwasaM, Kaito M, Ikoma J, Takeo M, Imoto I, Adachi Y, Yamauchi K, Koizumi R, Teraguchi S. Lactoferrin inhibits hepatitis C virus viremia in chronic hepatitisCpatients with high viral loads and HCV genotype 1b. American Journal of Gastroenterology 2002;97:766-767 (Pubitemid 34245920)
13. Kuipers ME, de Vries HG, Eikelboom MC, Meijer DK, Swart PJ. Synergistic fungistatic effects of lactoferrin in combination with antifungal drugs against clinical Candida isolates. Antimicrobial Agents and Chemotherapy 1999;43:2635-2641
14. Lawn JE,Wilczynska-Ketende K,Cousens SN. Estimating the causes of 4 million neonatal deaths in the year 2000. International Journal of Epidemiology 2006;35:706-718
15. Leitch EC, Willcox MD. Lactoferrin increases the susceptibility of S. epidermidis biofilms to lysozyme and vancomycin. Current Eye Research 1999;19:12-19.
16. Levy SB. Antimicrobial resistance: Bacteria on the defence. Resistance stems from misguided efforts to try to sterilize our environment. BMJ 1998;317:612-613
17. Lin PW, Stoll BJ. Necrotizing enterocolitis. Lancet 2006;368:1271-1283
18. Neish AS. Molecular aspects of intestinal epithelial cell-bacterial interactions that determine the development of intestinal inflammation. Inflammatory Bowel Diseases 2004;10:159-168
19. Nibbering PH, Ravensbergen E, Welling MM, van Berkel LA, van Berkel PH, Pauwels EK,Nuijens JH.Human lactoferrin and peptides derived from its N terminus are highly effective against infections with antibiotic-resistant bacteria. Infection and Immunity 2001;69: 1469-1476 (Pubitemid 32187596)
20. Speer CP. Inflammatory mechanisms in neonatal chronic lung disease. European Journal of Pediatrics 1999;158(suppl):S18-22.
21. Stoll BJ,HansenN, Fanaroff AA,Wright LL, CarloWA, Ehrenkranz RA, Lemons JA,Donovan EF, Stark AR, Tyson JE, OhW, et al.Lateonset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network. Pediatrics 2002;110:285-291
22. Stoll BJ, Hansen NI, Adams-Chapman I, Fanaroff AA, Hintz SR, Vohr B, Higgins RD. Neurodevelopmental and growth impairment among extremely low-birth-weight infants with neonatal infection. Jama 2004;19:2357-2365 (Pubitemid 39491920)
23. Stoll BJ. Infections of the neonatal infant. In: Behrman RE KR, Jenson HB editor(s). Nelson's Textbook of Pediatrics. Philadelphia: Saunders, 2004:623-640.
24. Stoll BJ, Hansen NI, Higgins RD, Fanaroff AA, Duara S, Goldberg R, Laptook A,Walsh M, Oh W, Hale E. Very low birth weight preterm infants with early onset neonatal sepsis: the predominance of gram-negative infections continues in the National Institute of Child Health and Human Development Neonatal Research Network, 2002-2003. Pediatric Infectious Disease Journal 2005;24:635-639 (Pubitemid 40993620)
25. Tanaka K, IkedaM,Nozaki A, KatoN, TsudaH, Saito S, SekiharaH. Lactoferrin inhibits hepatitis C virus viremia in patients with chronic hepatitis C: a pilot study. Japanese Journal of Cancer Research 1999; 90:367-371 (Pubitemid 29213539)
26. Tomita M,Wakabayashi H, Yamauchi K, Teraguchi S, HayasawaH. Bovine lactoferrin and lactoferricin derived from milk: production and applications. Biochemistry and Cell Biology 2002;80:109-112 (Pubitemid 34194235)
27. Trumpler U, Straub PW, Rosenmund A. Antibacterial prophylaxis with lactoferrin in neutropenic patients. European Journal of Clinical Microbiology and Infectious Diseases 1989;8:310-313 (Pubitemid 19111515)
28. Valenti P, AntoniniG. Lactoferrin: an important host defence against microbial and viral attack. Cellular andMolecular Life Sciences 2005; 62:2576-2587 (Pubitemid 41721231)
29. Verweij PE. A study on the tolerability and early efficacy of human lactoferrin peptide 1-11 (hlf 1-11) in patients with bacteremia due to S. epidermidis. ClinicalTrials.gov: NCT 00509847.
30. Verweij PE. A study on the tolerability and early efficacy of hLF 1-11 in patients with proven candidemia (SLIC). ClinicalTrials.gov: NCT 00509834.
31. Volpe JJ. Neurology of the Newborn. 3rd Edition. Philadelphia, London: WB Saunders, 1995.
32. Zaidi AKM,HuskinsWC, Thaver D, Bhutta ZA, Abbas Z,Goldman DA. Hospital-acquired neonatal infections in developing countries. Lancet 2005;365:1175-1188 (Pubitemid 40417568)